Brown Advisory Inc Bei Gene, Ltd. Transaction History

Brown Advisory Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$113.99 - $146.86 $1.29 Million - $1.66 Million	-11,287 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $1.39 Million - $1.71 Million	11,287 New	11,287 $1.49 Million
Q2 2018 Aug 10, 2018	SELL	$152.5 - $216.77 $23.6 Million - $33.6 Million	-155,022 Closed	0 $0
Q1 2018 Jun 28, 2018	BUY	$97.41 - $177.22 $6.26 Million - $11.4 Million	64,252 Added 70.79%	155,022 $26 Million
Q1 2018 May 14, 2018	SELL	$97.41 - $177.22 $19.9 Million - $36.2 Million	-204,304 Reduced 69.24%	90,770 $15.2 Million
Q4 2017 Feb 12, 2018	SELL	$79.6 - $114.73 $3.07 Million - $4.43 Million	-38,625 Reduced 11.57%	295,074 $28.8 Million
Q3 2017 Nov 13, 2017	SELL	$66.19 - $103.46 $9.8 Million - $15.3 Million	-148,003 Reduced 30.73%	333,699 $34.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	481,702	481,702 $21.7 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.